98.05% YTD


Moderna posted $1.2 billion in first quarter and expected to earn $6.20 /share on $4.41 billion in sales. The company already signed contracts worth $19.2 billion in product sales this year.

HOLD rating for $MRNA. With the buy zone in between $189.10-$198.56, the average high price target is still at $246 and an average low of $177.

Looking ahead to another milestone year for the company, it is currently sitting at a 98.05% increase YTD.
AdBlock Detected

We get it, advertisements are annoying!

But it's thanks to our sponsors that access to Trade2Win remains free for all. By viewing our ads you help us pay our bills, so please support the site and disable your AdBlocker.

I've Disabled AdBlock    No Thanks